Cadrenal Therapeutics

Historical price data

Cadrenal Therapeutics is a clinical-stage biotech focused on addressing critical gaps in anticoagulation therapy across acute and chronic settings. Its strategy leverages a differentiated pipeline of three assets targeting high-unmet-need, often orphan, cardiovascular and thrombotic disorders. Key achievements include advancing its lead asset, CAD-1005 for HIT, to Phase 3 readiness with Orphan Drug and Fast Track designations, and positioning tecarfarin for Phase 3 trials in end-stage kidney disease and LVAD patients. The company aims to deliver targeted therapies where current standards are inadequate or carry significant risk.

Focus on novel anticoagulant mechanisms, including a proprietary 12-lipoxygenase (12-LOX) inhibition platform for immune-mediated thrombosis and differentiated pharmacology within Vitamin K antagonism and Factor XIa inhibition.

Cadrenal competes in anticoagulation but uses niche strategy. In HIT, CAD-1005's novel mechanism faces existing supportive-care drugs. Tecarfarin targets warfarin in specific populations where DOACs fail. Frunexian, as an IV Factor XIa inhibitor, is differentiated from major pharma's oral chronic-use candidates in the same class.